The Market Impacts of Pharmaceutical Product Patents in Developing Countries: Evidence from India

S-Tier
Journal: American Economic Review
Year: 2016
Volume: 106
Issue: 1
Pages: 99-135

Authors (3)

Mark Duggan (not in RePEc) Craig Garthwaite (not in RePEc) Aparajita Goyal (World Bank Group)

Score contribution per author:

2.681 = (α=2.01 / 3 authors) × 4.0x S-tier

α: calibrated so average coauthorship-adjusted count equals average raw count

Abstract

In 2005, as the result of a World Trade Organization mandate, India implemented a patent reform for pharmaceuticals that was intended to comply with the 1995 Trade-Related Aspects of Intellectual Property Rights (TRIPS). Exploiting variation in the timing of patent decisions, we estimate that a molecule receiving a patent experienced an average price increase of just 3-6 percent, with larger increases for more recently developed molecules and for those produced by just one firm when the patent system began. Our results also show little impact on quantities sold or on the number of pharmaceutical firms operating in the market. (JEL K33, L11, L13, L65, O14, O34, O38)

Technical Details

RePEc Handle
repec:aea:aecrev:v:106:y:2016:i:1:p:99-135
Journal Field
General
Author Count
3
Added to Database
2026-01-25